EP 4263585 A1 20231025 - TL1A THERAPY COMPOSITIONS AND METHODS OF TREATMENT THEREWITH
Title (en)
TL1A THERAPY COMPOSITIONS AND METHODS OF TREATMENT THEREWITH
Title (de)
TL1A-THERAPIEZUSAMMENSETZUNGEN UND BEHANDLUNGSVERFAHREN DAMIT
Title (fr)
COMPOSITIONS THÉRAPEUTIQUES DE TL1A ET MÉTHODES DE TRAITEMENT LES UTILISANT
Publication
Application
Priority
- US 202063128749 P 20201221
- US 2021064406 W 20211220
Abstract (en)
[origin: WO2022140283A1] Disclosed herein are methods, kits and compositions for treating an inflammatory disease or condition, or fibrosis in a subject that has been determined to have increased fold-change in Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) expression based, at least partially, on a presence of a combination of genotypes detected in a sample obtained from the subject. In some embodiments, the combination of genotypes is significantly associated with the increased fold-change in TL1A, and in some cases, may also be predictive of severe forms of the inflammatory disease or condition. In some embodiments, the inflammatory disease or condition is an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
IPC 8 full level
C07K 14/525 (2006.01); A61P 1/00 (2006.01); C12Q 1/6883 (2018.01)
CPC (source: EP US)
A61P 1/00 (2017.12 - EP US); C07K 14/70575 (2013.01 - EP); C07K 16/2875 (2013.01 - US); C12Q 1/6883 (2013.01 - EP US); A61K 2039/505 (2013.01 - US); C12Q 2600/156 (2013.01 - EP US); C12Q 2600/158 (2013.01 - EP US)
Citation (search report)
See references of WO 2022140283A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022140283 A1 20220630; CA 3202510 A1 20220630; EP 4263585 A1 20231025; US 2023304095 A1 20230928
DOCDB simple family (application)
US 2021064406 W 20211220; CA 3202510 A 20211220; EP 21911988 A 20211220; US 202318334221 A 20230613